← Eichor
Study identifier: NCT06313827 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

e-Health Program to Prevent Exacerbations in the Cystic Fibrosis Population

Condition: Cystic Fibrosis  ·  Sponsor: University of Valencia

PhaseNA
Planned participants60
Who can joinAll sexes, 6 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this clinical trial is to analyse the impact of a telematic assessment and monitoring protocol in people with cystic fibrosis, in order to identify exacerbations early, thus preventing loss of lung function and maintaining quality of life. Participants will be assigned to one of 3 study groups: Control group (CG-1): will receive their usual physiotherapy treatment; Treatment group (TG-2): will receive their usual physiotherapy treatment, plus explanation of the use of the monitoring equipment; Treatment and follow-up group (TGF-3): will receive their usual physiotherapy treatment, plus explanation of the use of the monitoring equipment, plus telematic control of exacerbations with feedback from the physiotherapist.

This description comes directly from the study's public registry record.

Talk to the study team

Francisco Martinez-Arnau, PhD  ·  0034963983853  ·  francisco.m.martinez@uv.es

Always discuss trial participation with your own doctor first.

Locations (1)

Instalaciones de la Universitat de ValenciaValencia, SpainRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06313827